reverse-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
| Property | Value | Notes |
|---|---|---|
| Dry storage temperature | -20 C or below | Sealed, desiccated, protected from light |
| Solution stability | Hours to days at 2-8 C | Depends on buffer and microbial load |
| Preferred pH range | Near neutral to slightly acidic | Alkaline pH accelerates hydrolysis |
| Main degradation routes | Hydrolysis and deamidation | No cysteine or methionine in sequence |
| Identity confirmation | Electrospray mass spectrometry | Observed mass compared with 751.9 Da |
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
William Dale Archerd (May 5, 1912 – October 29, 1977) was an American serial killer who killed at least three people with insulin injections between 1956 and 1966 in Northern California. He was the first to be convicted of using insulin as a murder weapon in the US, and he is suspected in three more cases.
Now EC 1.1.1.303, diacetyl reductase [(R)-acetoin forming] and EC 1.1.1.304, diacetyl reductase [(S)-acetoin forming] EC 1.1.1.6: glycerol dehydrogenase EC 1.1.1.7: propanediol-phosphate dehydrogenase EC 1.1.1.8: glycerol-3-phosphate dehydrogenase (NAD+) EC 1.1.1.9: D-xylulose reductase EC 1.1.1.10: L-xylulose reductase EC 1.1.1.11: D-arabinitol 4-dehydrogenase EC 1.1.1.12: L-arabinitol 4-dehydrogenase EC 1.1.1.13: L-arabinitol 2-dehydrogenase EC 1.1.1.14: L-iditol 2-dehydrogenase EC 1.1.1.15: D-iditol 2-dehydrogenase EC 1.1.1.16: galactitol 2-dehydrogenase EC 1.1.1.17: mannitol-1-phosphate 5-dehydrogenase EC 1.1.1.18: inositol 2-dehydrogenase EC 1.1.1.19: glucuronate reductase EC 1.1.1.20: glucuronolactone reductase EC 1.1.1.207: (-)-menthol dehydrogenase EC 1.1.1.208: (+)-neomenthol dehydrogenase EC 1.1.1.21: aldose reductase EC 1.1.1.22: UDP-glucose 6-dehydrogenase EC 1.1.1.222: (R)-4-hydroxyphenyllactate dehydrogenase EC 1.1.1.23: histidinol dehydrogenase| EC 1.1.1.24: quinate/shikimate dehydrogenase (NAD+) EC 1.1.1.25: shikimate dehydrogenase (NADP+) EC 1.1.1.26: glyoxylate reductase EC 1.1.1.27: L-lactate dehydrogenase EC 1.1.1.28: D-lactate dehydrogenase EC 1.1.1.29: glycerate dehydrogenase EC 1.1.1.30: 3-hydroxybutyrate dehydrogenase EC 1.1.1.31: 3-hydroxyisobutyrate dehydrogenase EC 1.1.1.32: mevaldate reductase EC 1.1.1.33: mevaldate reductase (NADPH) EC 1.1.1.34: hydroxymethylglutaryl-CoA reductase (NADPH) EC 1.1.1.35: 3-hydroxyacyl-CoA dehydrogenase EC 1.1.1.36: acetoacetyl-CoA reductase EC 1.1.1.37: malate dehydrogenase EC 1.1.1.38: malate dehydrogenase (oxaloacetate-decarboxylating) EC 1.1.1.39: malate dehydrogenase (decarboxylating) EC 1.1.1.40: malate dehydrogenase (oxaloacetate-decarboxylating) (NADP+) EC 1.1.1.41: isocitrate dehydrogenase (NAD+) EC 1.1.1.42: isocitrate dehydrogenase (NADP+) EC 1.1.1.43: phosphogluconate 2-dehydrogenase EC 1.1.1.44: phosphogluconate dehydrogenase (NADP+-dependent, decarboxylating) EC 1.1.1.45: L-gulonate 3-dehydrogenase EC 1.1.1.46: L-arabinose 1-dehydrogenase EC 1.1.1.47: glucose 1-dehydrogenase [NAD(P)+)] EC 1.1.1.48: D-galactose 1-dehydrogenase EC 1.1.1.49: glucose-6-phosphate dehydrogenase (NADP+) EC 1.1.1.50: 3α-hydroxysteroid 3-dehydrogenase (Si-specific) EC 1.1.1.51: 3(or 17)β-hydroxysteroid dehydrogenase EC 1.1.1.52: 3α-hydroxycholanate dehydrogenase (NAD+) EC 1.1.1.53: 3α(or 20β)-hydroxysteroid dehydrogenase EC 1.1.1.54: allyl-alcohol dehydrogenase EC 1.1.1.55: lactaldehyde reductase (NADPH) EC 1.1.1.56: ribitol 2-dehydrogenase EC 1.1.1.57: fructuronate reductase EC 1.1.1.58: tagaturonate reductase EC 1.1.1.59: 3-hydroxypropionate dehydrogenase EC 1.1.1.60: 2-hydroxy-3-oxopropionate reductase EC 1.1.1.61: 4-hydroxybutyrate dehydrogenase EC 1.1.1.62: 17β-estradiol 17-dehydrogenase EC 1.1.1.63: testosterone 17β-dehydrogenase. Now EC 1.1.1.239, 3α(17β)-hydroxysteroid dehydrogenase (NAD+) EC 1.1.1.64: testosterone 17β-dehydrogenase (NADP+) EC 1.1.1.65: pyridoxine 4-dehydrogenase EC 1.1.1.66: ω-hydroxydecanoate dehydrogenase EC 1.1.1.67: mannitol 2-dehydrogenase EC 1.1.1.68: 5,10-methylenetetrahydrofolate reductase. Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.1.69: gluconate 5-dehydrogenase EC 1.1.1.70: D-glucuronolactone dehydrogenase. Now included with EC 1.2.1.3 aldehyde dehydrogenase (NAD+) EC 1.1.1.71: alcohol dehydrogenase [NAD(P)+] EC 1.1.1.72: glycerol dehydrogenase (NADP+) EC 1.1.1.73: octanol dehydrogenase EC 1.1.1.74: D-aminopropanol dehydrogenase (reaction due to EC 1.1.1.4 (R,R)-butanediol dehydrogenase) EC 1.1.1.75: (R)-aminopropanol dehydrogenase EC 1.1.1.76: (S,S)-butanediol dehydrogenase EC 1.1.1.77: lactaldehyde reductase EC 1.1.1.78: methylglyoxal reductase (NADH-dependent) EC 1.1.1.79: glyoxylate reductase (NADP+) EC 1.1.1.80: isopropanol dehydrogenase (NADP+) EC 1.1.1.81: hydroxypyruvate reductase EC 1.1.1.82: malate dehydrogenase (NADP+) EC 1.1.1.83: D-malate dehydrogenase (decarboxylating) EC 1.1.1.84: dimethylmalate dehydrogenase EC 1.1.1.85: 3-isopropylmalate dehydrogenase EC 1.1.1.86: ketol-acid reductoisomerase (NADP+) EC 1.1.1.87: homoisocitrate dehydrogenase EC 1.1.1.88: hydroxymethylglutaryl-CoA reductase EC 1.1.1.89: dihydroxyisovalerate dehydrogenase (isomerizing). Now included with EC 1.1.1.86 ketol-acid reductoisomerase EC 1.1.1.90: aryl-alcohol dehydrogenase EC 1.1.1.91: aryl-alcohol dehydrogenase (NADP+) EC 1.1.1.92: oxaloglycolate reductase (decarboxylating) EC 1.1.1.93: tartrate dehydrogenase EC 1.1.1.94: glycerol-3-phosphate dehydrogenase [NAD(P)+] EC 1.1.1.95: phosphoglycerate dehydrogenase EC 1.1.1.96: diiodophenylpyruvate reductase EC 1.1.1.97: 3-hydroxybenzyl-alcohol dehydrogenase EC 1.1.1.98: (R)-2-hydroxy-fatty-acid dehydrogenase EC 1.1.1.99: (S)-2-hydroxy-fatty-acid dehydrogenase EC 1.1.1.100: 3-oxoacyl-[acyl-carrier-protein] reductase EC 1.1.1.101: acylglycerone-phosphate reductase EC 1.1.1.102: 3-dehydrosphinganine reductase EC 1.1.1.103: L-threonine 3-dehydrogenase EC 1.1.1.104: 4-oxoproline reductase EC 1.1.1.105: all-trans-retinol dehydrogenase (NAD+) EC 1.1.1.106: pantoate 4-dehydrogenase EC 1.1.1.107: pyridoxal 4-dehydrogenase EC 1.1.1.108: carnitine 3-dehydrogenase EC 1.1.1.109: Now EC 1.3.1.28, 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase EC 1.1.1.110: aromatic 2-oxoacid reductase EC 1.1.1.111: 3-(imidazol-5-yl)lactate dehydrogenase EC 1.1.1.112: indanol dehydrogenase EC 1.1.1.113: L-xylose 1-dehydrogenase EC 1.1.1.114: apiose 1-reductase EC 1.1.1.115: ribose 1-dehydrogenase (NADP+) EC 1.1.1.116: D-arabinose 1-dehydrogenase (NAD+) EC 1.1.1.117: D-arabinose 1-dehydrogenase [NAD(P)+] EC 1.1.1.118: glucose 1-dehydrogenase (NAD+) EC 1.1.1.119: glucose 1-dehydrogenase (NADP+) EC 1.1.1.120: galactose 1-dehydrogenase (NADP+) EC 1.1.1.121: aldose 1-dehydrogenase (NAD+) EC 1.1.1.122: D-threo-aldose 1-dehydrogenase EC 1.1.1.123: sorbose 5-dehydrogenase (NADP+) EC 1.1.1.124: fructose 5-dehydrogenase (NADP+) EC 1.1.1.125: 2-deoxy-D-gluconate 3-dehydrogenase EC 1.1.1.126: 2-dehydro-3-deoxy-D-gluconate 6-dehydrogenase EC 1.1.1.127: 2-dehydro-3-deoxy-D-gluconate 5-dehydrogenase EC 1.1.1.128: The reaction described is covered by EC 1.1.1.264, L-idonate 5-dehydrogenase. EC 1.1.1.129: L-threonate 3-dehydrogenase EC 1.1.1.130: 3-dehydro-L-gulonate 2-dehydrogenase EC 1.1.1.131: mannuronate reductase EC 1.1.1.132: GDP-mannose 6-dehydrogenase EC 1.1.1.133: dTDP-4-dehydrorhamnose reductase EC 1.1.1.134: dTDP-6-deoxy-L-talose 4-dehydrogenase (NADP+) EC 1.1.1.135: GDP-6-deoxy-D-talose 4-dehydrogenase EC 1.1.1.136: UDP-N-acetylglucosamine 6-dehydrogenase EC 1.1.1.137: ribitol-5-phosphate 2-dehydrogenase EC 1.1.1.138: mannitol 2-dehydrogenase (NADP+) EC 1.1.1.139: polyol dehydrogenase (NADP+). Now included with EC 1.1.1.21 aldehyde reductase EC 1.1.1.140: sorbitol-6-phosphate 2-dehydrogenase EC 1.1.1.141: 15-hydroxyprostaglandin dehydrogenase (NAD+) EC 1.1.1.142: D-pinitol dehydrogenase EC 1.1.1.143: sequoyitol dehydrogenase EC 1.1.1.144: perillyl-alcohol dehydrogenase EC 1.1.1.145: 3β-hydroxy-Δ5-steroid dehydrogenase EC 1.1.1.146: 11β-hydroxysteroid dehydrogenase EC 1.1.1.147: 16α-hydroxysteroid dehydrogenase EC 1.1.1.148: estradiol 17α-dehydrogenase EC 1.1.1.149: 20α-hydroxysteroid dehydrogenase EC 1.1.1.150: 21-hydroxysteroid dehydrogenase (NAD+) EC 1.1.1.151: 21-hydroxysteroid dehydrogenase (NADP+) EC 1.1.1.152: 3α-hydroxy-5β-androstane-17-one 3α-dehydrogenase EC 1.1.1.153: sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming) EC 1.1.1.154: ureidoglycolate dehydrogenase EC 1.1.1.155: homoisocitrate dehydrogenase. The enzyme is identical to EC 1.1.1.87, homoisocitrate dehydrogenase EC 1.1.1.156: glycerol 2-dehydrogenase (NADP+) EC 1.1.1.157: 3-hydroxybutyryl-CoA dehydrogenase EC 1.1.1.158: Now EC 1.3.1.98, UDP-N-acetylmuramate dehydrogenase EC 1.1.1.159: 7α-hydroxysteroid dehydrogenase EC 1.1.1.160: dihydrobunolol dehydrogenase EC 1.1.1.161: The activity is part of EC 1.14.13.15, cholestanetriol 26-monooxygenase EC 1.1.1.162: erythrulose reductase EC 1.1.1.163: cyclopentanol dehydrogenase EC 1.1.1.164: hexadecanol dehydrogenase EC 1.1.1.165: 2-alkyn-1-ol dehydrogenase EC 1.1.1.166: hydroxycyclohexanecarboxylate dehydrogenase EC 1.1.1.167: hydroxymalonate dehydrogenase EC 1.1.1.168: 2-dehydropantolactone reductase (Re-specific) EC 1.1.1.169: 2-dehydropantoate 2-reductase EC 1.1.1.170: 3β-hydroxysteroid-4α-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.171: Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.1.172: 2-oxoadipate reductase EC 1.1.1.173: L-rhamnose 1-dehydrogenase EC 1.1.1.174: cyclohexane-1,2-diol dehydrogenase EC 1.1.1.175: D-xylose 1-dehydrogenase EC 1.1.1.176: 12α-hydroxysteroid dehydrogenase EC 1.1.1.177: glycerol-3-phosphate 1-dehydrogenase (NADP+) EC 1.1.1.178: 3-hydroxy-2-methylbutyryl-CoA dehydrogenase EC 1.1.1.179: D-xylose 1-dehydrogenase (NADP+, D-xylono-1,5-lactone-forming) EC 1.1.1.180: Now included with EC 1.1.1.131 mannuronate reductase EC 1.1.1.181: cholest-5-ene-3β,7α-diol 3β-dehydrogenase EC 1.1.1.182: Now included with EC 1.1.1.198 (+)-borneol dehydrogenase, EC 1.1.1.227 (-)-borneol dehydrogenase and EC 1.1.1.228 (+)-sabinol dehydrogenase EC 1.1.1.183: geraniol dehydrogenase (NADP+) EC 1.1.1.184: carbonyl reductase (NADPH) EC 1.1.1.185: L-glycol dehydrogenase EC 1.1.1.186: dTDP-galactose 6-dehydrogenase EC 1.1.1.187: GDP-4-dehydro-D-rhamnose reductase EC 1.1.1.188: prostaglandin-F synthase EC 1.1.1.189: prostaglandin-E2 9-reductase EC 1.1.1.190: indole-3-acetaldehyde reductase (NADH) EC 1.1.1.191: indole-3-acetaldehyde reductase (NADPH) EC 1.1.1.192: long-chain-alcohol dehydrogenase EC 1.1.1.193: 5-amino-6-(5-phosphoribosylamino)uracil reductase EC 1.1.1.194: coniferyl-alcohol dehydrogenase EC 1.1.1.195: cinnamyl-alcohol dehydrogenase EC 1.1.1.196: 15-hydroxyprostaglandin-D dehydrogenase (NADP+) EC 1.1.1.197: 15-hydroxyprostaglandin dehydrogenase (NADP+) EC 1.1.1.198: (+)-borneol dehydrogenase EC 1.1.1.199: (S)-usnate reductase EC 1.1.1.200: aldose-6-phosphate reductase (NADPH) EC 1.1.1.228: (+)-sabinol dehydrogenase EC 1.1.1.251: galactitol-1-phosphate 5-dehydrogenase EC 1.1.1.252: tetrahydroxynaphthalene reductase EC 1.1.1.253: Now EC 1.5.1.33, pteridine reductase EC 1.1.1.254: (S)-carnitine 3-dehydrogenase EC 1.1.1.255: mannitol dehydrogenase EC 1.1.1.256: fluoren-9-ol dehydrogenase EC 1.1.1.257: 4-(hydroxymethyl)benzenesulfonate dehydrogenase EC 1.1.1.258: 6-hydroxyhexanoate dehydrogenase EC 1.1.1.259: 3-hydroxypimeloyl-CoA dehydrogenase EC 1.1.1.260: sulcatone reductase EC 1.1.1.261: sn-glycerol-1-phosphate dehydrogenase EC 1.1.1.262: 4-hydroxythreonine-4-phosphate dehydrogenase EC 1.1.1.263: 1,5-anhydro-D-fructose reductase EC 1.1.1.264: L-idonate 5-dehydrogenase EC 1.1.1.265: 3-methylbutanal reductase EC 1.1.1.266: dTDP-4-dehydro-6-deoxyglucose reductase EC 1.1.1.267: 1-deoxy-D-xylulose-5-phosphate reductoisomerase EC 1.1.1.268: 2-(R)-hydroxypropyl-CoM dehydrogenase EC 1.1.1.269: 2-(S)-hydroxypropyl-CoM dehydrogenase EC 1.1.1.270: 3β-hydroxysteroid 3-dehydrogenase EC 1.1.1.271: GDP-L-fucose synthase EC 1.1.1.272: D-2-hydroxyacid dehydrogenase (NADP+) EC 1.1.1.273: vellosimine dehydrogenase EC 1.1.1.274: 2,5-didehydrogluconate reductase (2-dehydro-D-gluconate-forming) EC 1.1.1.275: (+)-trans-carveol dehydrogenase EC 1.1.1.276: serine 3-dehydrogenase (NADP+) EC 1.1.1.277: 3β-hydroxy-5β-steroid dehydrogenase EC 1.1.1.278: 3β-hydroxy-5α-steroid dehydrogenase EC 1.1.1.279: (R)-3-hydroxyacid-ester dehydrogenase EC 1.1.1.280: (S)-3-hydroxyacid-ester dehydrogenase EC 1.1.1.281: GDP-4-dehydro-6-deoxy-D-mannose reductase EC 1.1.1.282: Quinate/shikimate dehydrogenase EC 1.1.1.283: methylglyoxal reductase (NADPH-dependent) EC 1.1.1.284: S-(hydroxymethyl)glutathione dehydrogenase EC 1.1.1.285: 3′′-deamino-3′′-oxonicotianamine reductase EC 1.1.1.286: isocitrate—homoisocitrate dehydrogenase EC 1.1.1.287: D-arabinitol dehydrogenase (NADP+) EC 1.1.1.288: xanthoxin dehydrogenase EC 1.1.1.289: sorbose reductase EC 1.1.1.290: 4-phosphoerythronate dehydrogenase EC 1.1.1.291: 2-hydroxymethylglutarate dehydrogenase EC 1.1.1.292: 1,5-anhydro-D-fructose reductase (1,5-anhydro-D-mannitol-forming) EC 1.1.1.293: tropinone reductase I. This enzyme was already in the Enzyme List as EC 1.1.1.206, tropine dehydrogenase so EC 1.1.1.293 has been withdrawn at the public-review stage EC 1.1.1.294: chlorophyll(ide) b reductase EC 1.1.1.295: momilactone-A synthase EC 1.1.1.296: dihydrocarveol dehydrogenase EC 1.1.1.297: limonene-1,2-diol dehydrogenase EC 1.1.1.298: 3-hydroxypropionate dehydrogenase (NADP+) EC 1.1.1.299: malate dehydrogenase [NAD(P)+)] EC 1.1.1.300: NADP-retinol dehydrogenase EC 1.1.1.301: D-arabitol-phosphate dehydrogenase EC 1.1.1.302: 2,5-diamino-6-(ribosylamino)-4(3H)-pyrimidinone 5′-phosphate reductase EC 1.1.1.303: Diacetyl reductase ((R)-acetoin forming) EC 1.1.1.304: Diacetyl reductase ((S)-acetoin forming) EC 1.1.1.305: UDP-glucuronic acid dehydrogenase (UDP-4-keto-hexauronic acid decarboxylating) EC 1.1.1.306: S-(hydroxymethyl)mycothiol dehydrogenase EC 1.1.1.307: D-xylose reductase EC 1.1.1.308: sulfopropanediol 3-dehydrogenase EC 1.1.1.309: phosphonoacetaldehyde reductase (NADH) EC 1.1.1.310: (S)-sulfolactate dehydrogenase EC 1.1.1.311: (S)-1-phenylethanol dehydrogenase EC 1.1.1.312: 2-hydroxy-4-carboxymuconate semialdehyde hemiacetal dehydrogenase EC 1.1.1.313: sulfoacetaldehyde reductase EC 1.1.1.314: Now known to be catalyzed by EC 1.14.14.95, germacrene A hydroxylase EC 1.1.1.315: 11-cis-retinol dehydrogenase EC 1.1.1.316: L-galactose 1-dehydrogenase EC 1.1.1.317: perakine reductase EC 1.1.1.318: eugenol synthase EC 1.1.1.319: isoeugenol synthase EC 1.1.1.320: benzil reductase [(S)-benzoin forming] EC 1.1.1.321: benzil reductase [(R)-benzoin forming] EC 1.1.1.322: (–)-endo-fenchol dehydrogenase EC 1.1.1.323: (+)-thujan-3-ol dehydrogenase EC 1.1.1.324: 8-hydroxygeraniol dehydrogenase EC 1.1.1.325: sepiapterin reductase (L-threo-7,8-dihydrobiopterin forming) EC 1.1.1.326: zerumbone synthase EC 1.1.1.327: 5-exo-hydroxycamphor dehydrogenase EC 1.1.1.328: nicotine blue oxidoreductase EC 1.1.1.329: 2-deoxy-scyllo-inosamine dehydrogenase EC 1.1.1.330: very-long-chain 3-oxoacyl-CoA reductase EC 1.1.1.331: secoisolariciresinol dehydrogenase EC 1.1.1.332: chanoclavine-I dehydrogenase EC 1.1.1.333: decaprenylphospho-β-D-erythro-pentofuranosid-2-ulose 2-reductase EC 1.1.1.334: methylecgonone reductase EC 1.1.1.335: UDP-N-acetyl-2-amino-2-deoxyglucuronate dehydrogenase EC 1.1.1.336: UDP-N-acetyl-D-mannosamine dehydrogenase EC 1.1.1.337: L-2-hydroxycarboxylate dehydrogenase (NAD+) EC 1.1.1.338: (2R)-3-sulfolactate dehydrogenase (NADP+) EC 1.1.1.339: dTDP-6-deoxy-L-talose 4-dehydrogenase (NAD+) EC 1.1.1.340: 1-deoxy-11β-hydroxypentalenate dehydrogenase EC 1.1.1.341: CDP-abequose synthase EC 1.1.1.342: CDP-paratose synthase EC 1.1.1.343: phosphogluconate dehydrogenase (NAD+-dependent, decarboxylating) EC 1.1.1.344: dTDP-6-deoxy-L-talose 4-dehydrogenase [NAD(P)+] EC 1.1.1.345: D-2-hydroxyacid dehydrogenase (NAD+) EC 1.1.1.346: 2,5-didehydrogluconate reductase (2-dehydro-L-gulonate-forming) EC 1.1.1.347: geraniol dehydrogenase (NAD+) EC 1.1.1.348: (3R)-2′-hydroxyisoflavanone reductase EC 1.1.1.349: norsolorinic acid ketoreductase EC 1.1.1.350: ureidoglycolate dehydrogenase (NAD+) EC 1.1.1.351: phosphogluconate dehydrogenase [NAD(P)+-dependent, decarboxylating] EC 1.1.1.352: 5′-hydroxyaverantin dehydrogenase EC 1.1.1.353: versiconal hemiacetal acetate reductase EC 1.1.1.354: farnesol dehydrogenase (NAD+) EC 1.1.1.355: 2′-dehydrokanamycin reductase EC 1.1.1.356: GDP-L-colitose synthase EC 1.1.1.357: 3α-hydroxysteroid 3-dehydrogenase EC 1.1.1.358: 2-dehydropantolactone reductase EC 1.1.1.359: aldose 1-dehydrogenase [NAD(P)+] EC 1.1.1.360: glucose/galactose 1-dehydrogenase EC 1.1.1.361: glucose-6-phosphate 3-dehydrogenase EC 1.1.1.362: aklaviketone reductase EC 1.1.1.363: glucose-6-phosphate dehydrogenase [NAD(P)+] EC 1.1.1.364: dTDP-4-dehydro-6-deoxy-α-D-gulose 4-ketoreductase EC 1.1.1.365: D-galacturonate reductase EC 1.1.1.366: L-idonate 5-dehydrogenase (NAD+) EC 1.1.1.367: UDP-2-acetamido-2,6-β-L-arabino-hexul-4-ose reductase EC 1.1.1.368: 6-hydroxycyclohex-1-ene-1-carbonyl-CoA dehydrogenase EC 1.1.1.369: D-chiro-inositol 1-dehydrogenase EC 1.1.1.370: scyllo-inositol 2-dehydrogenase (NAD+) EC 1.1.1.371: scyllo-inositol 2-dehydrogenase (NADP+) EC 1.1.1.372: D/L-glyceraldehyde reductase EC 1.1.1.373: sulfolactaldehyde 3-reductase EC 1.1.1.374: UDP-N-acetylglucosamine 3-dehydrogenase EC 1.1.1.375: L-2-hydroxycarboxylate dehydrogenase [NAD(P)+] EC 1.1.1.376: L-arabinose 1-dehydrogenase [NAD(P)+] EC 1.1.1.377: L-rhamnose 1-dehydrogenase (NADP+) EC 1.1.1.378: L-rhamnose 1-dehydrogenase [NAD(P)+] EC 1.1.1.379: (R)-mandelate dehydrogenase EC 1.1.1.380: L-gulonate 5-dehydrogenase EC 1.1.1.381: 3-hydroxy acid dehydrogenase EC 1.1.1.382: ketol-acid reductoisomerase (NAD+) EC 1.1.1.383: ketol-acid reductoisomerase [NAD(P)+] EC 1.1.1.384: dTDP-3,4-didehydro-2,6-dideoxy-α-D-glucose 3-reductase EC 1.1.1.385: dihydroanticapsin dehydrogenase EC 1.1.1.386: ipsdienol dehydrogenase EC 1.1.1.387: L-serine 3-dehydrogenase (NAD+) EC 1.1.1.388: glucose-6-phosphate dehydrogenase (NAD+) EC 1.1.1.389: 2-dehydro-3-deoxy-L-galactonate 5-dehydrogenase EC 1.1.1.390: sulfoquinovose 1-dehydrogenase EC 1.1.1.391: 3β-hydroxycholanate 3-dehydrogenase (NAD+) EC 1.1.1.392: 3α-hydroxycholanate dehydrogenase (NADP+) EC 1.1.1.393: 3β-hydroxycholanate 3-dehydrogenase (NADP+) EC 1.1.1.394: aurachin B dehydrogenase EC 1.1.1.395: 3α-hydroxy bile acid-CoA-ester 3-dehydrogenase EC 1.1.1.396: bacteriochlorophyllide a dehydrogenase EC 1.1.1.397: β-methylindole-3-pyruvate reductase EC 1.1.1.398: 2-glutathionyl-2-methylbut-3-en-1-ol dehydrogenase EC 1.1.1.399: 2-oxoglutarate reductase EC 1.1.1.400: 2-methyl-1,2-propanediol dehydrogenase EC 1.1.1.401: 2-dehydro-3-deoxy-L-rhamnonate dehydrogenase (NAD+) EC 1.1.1.402: D-erythritol 1-phosphate dehydrogenase EC 1.1.1.403: D-threitol dehydrogenase (NAD+) EC 1.1.1.404: tetrachlorobenzoquinone reductase EC 1.1.1.405: ribitol-5-phosphate 2-dehydrogenase (NADP+) EC 1.1.1.406: galactitol 2-dehydrogenase (L-tagatose-forming) EC 1.1.1.407: D-altritol 5-dehydrogenase EC 1.1.1.408: 4-phospho-D-threonate 3-dehydrogenase EC 1.1.1.409: 4-phospho-D-erythronate 3-dehydrogenase EC 1.1.1.410: D-erythronate 2-dehydrogenase EC 1.1.1.411: L-threonate 2-dehydrogenase EC 1.1.1.412: 2-alkyl-3-oxoalkanoate reductase EC 1.1.1.413: A-factor type γ-butyrolactone 1′-reductase (1S-forming) EC 1.1.1.414: L-galactonate 5-dehydrogenase EC 1.1.1.415: noscapine synthase EC 1.1.1.416: isopyridoxal dehydrogenase (5-pyridoxolactone-forming) EC 1.1.1.417: 3β-hydroxysteroid-4β-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.418: plant 3β-hydroxysteroid-4α-carboxylate 3-dehydrogenase (decarboxylating) EC 1.1.1.419: nepetalactol dehydrogenase EC 1.1.1.420: D-apiose dehydrogenase EC 1.1.1.421: D-apionate oxidoisomerase EC 1.1.1.422: pseudoephedrine dehydrogenase EC 1.1.1.423: (1R,2S)-ephedrine 1-dehydrogenase EC 1.1.1.424: D-xylose 1-dehydrogenase (NADP+, D-xylono-1,4-lactone-forming) EC 1.1.1.425: levoglucosan dehydrogenase EC 1.1.1.426: UDP-N-acetyl-α-D-quinovosamine dehydrogenase
== Relationship to other South Asians and West Asians == A 1985 study conducted by Roychoudhury AK and Nei M indicating the values of genetic distance showed that the Sinhalese, along with the four Indian subcontinent populations from Punjab, Gujarat, Andhra Pradesh, and Bangladesh, were closer to Afghans and Iranians than the neighboring East/Southeast Asian groups represented by the Bhutanese, Malays, Bataks in northern Sumatra, and the Chinese.
Sources: en.wikipedia.org
Everyone has the right to food and water, and under the Charter of Fundamental Rights of the EU "the improvement of the quality of the environment must be integrated into the policies of the Union". The Common Agricultural Policy's origins lay in ensuring that all farm workers had fair wages and everyone had food, since in 1960 a third of employment and a fifth of GDP was in agriculture, and after WW2 Europe had been on the brink of starvation. In 2020, the agricultural workforce was 4.2% of the EU total. The CAP's objectives are still to increase production, "a fair standard of living for the agricultural community", to stabilise markets and supplies, and "reasonable prices" for consumers. In 2021, the CAP was 33.1% of the entire EU budget, at €55.1 billion, however there are no requirements for subsidies to be used so that farm workers (as opposed to owners) have fair pay scales, few requirements for rural development, and minimal standards for environmental improvement.
=== Advanced platelet-rich fibrin === Blood-derived growth factors have been used in medicine and oral surgery for more than twenty years with an abundance of scientific data supporting its role in soft and hard tissue regeneration. APRF, introduced by Dr. Joseph Choukroun, represents the fourth improved generation of such technology and has been widely used in the field of dentistry and oral surgery. Advantages of APRF include no risk of rejection or disease transmission (using your own blood) and improved healing (autogenous growth factors, hematopoietic or mesenchymal stem cells).
Blood plasma volume may be expanded by or drained to extravascular fluid when there are changes in Starling forces across capillary walls. For example, when blood pressure drops in circulatory shock, Starling forces drive fluid into the interstitium, causing third spacing. Standing still for a prolonged period will cause an increase in transcapillary hydrostatic pressure. As a result, approximately 12% of blood plasma volume will cross into the extravascular compartment. This plasma shift causes an increase in hematocrit, serum total protein, blood viscosity and, as a result of increased concentration of coagulation factors, it causes orthostatic hypercoagulability.
It also condemned Israel's attacks on Syrian territory and its "continued violations of international laws and norms". Hamas: Hamas issued a statement expressing full solidarity with Syria and described the Israeli attacks as a "blatant violation of international laws" and called for a strong response to confront them. Hezbollah: Hezbollah condemned the Israeli strikes, describing them as against international law.
Sources: en.wikipedia.org
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.
Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.
Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.